Trial Profile
Trial of Vaccine Therapy in Curative Resected Prostate Cancer Patients Using Autologous Dendritic Cells Loaded With mRNA From Primary Prostate Cancer Tissue, hTERT and Survivin
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2023
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccines-Medigene Immnotherapies (Primary)
- Indications Prostate cancer
- Focus First in man; Therapeutic Use
- 02 Feb 2023 Status changed from active, no longer recruiting to completed.
- 25 Jan 2021 Planned primary completion date changed from 1 Sep 2020 to 1 Sep 2024.
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology